No Data
No Data
Express News | Werewolf Therapeutics: Cash & Cash Equivalents as of June 30 Enough to Fund Operational Expenses & Capex Requirements Through at Least Q1 2026
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
Werewolf Therapeutics | 10-Q: Quarterly report
Werewolf Therapeutics 2Q Loss/Shr 43c >HOWL
Werewolf Therapeutics 2Q Loss $17.2M >HOWL
Werewolf Therapeutics 2Q Rev $1.14M >HOWL
No Data